Mast Therapeutics, Inc. is a biopharmaceutical company. The Company develops clinical-stage therapies for serious or life-threatening diseases with unmet needs. The Company focuses on developing new therapies for sickle cell disease, a chronic and genetic disorder classified as a rare, or orphan, disease in the United States of America and European Union, and for heart failure, a condition with an unmet need for treatment options. The Company's segment is engaged in the business of developing therapies for serious or life-threatening diseases. The Company focuses on its Molecular Adhesion and Sealant Technology (MAST) platform, to develop MST-188 (vepoloxamer) Injection, its lead product candidate. The Company also develops AIR001, a sodium nitrite solution for intermittent inhalation through nebulizer. The Company's AIR001 is in Phase II clinical development for the treatment of patients with HFpEF.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NYSE:MSTX
- CUSIP: N/A
- Web: N/A
- 50 Day Moving Avg: $0.12
- 200 Day Moving Avg: $0.11
- 52 Week Range: $0.07 - $0.71
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.77
- P/E Growth: 0.000
- Average Volume: 5.10 million shs.
Frequently Asked Questions for Mast Therapeutics (NYSE:MSTX)
What is Mast Therapeutics' stock symbol?
Mast Therapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "MSTX."
How were Mast Therapeutics' earnings last quarter?
Mast Therapeutics Inc (NYSE:MSTX) announced its earnings results on Tuesday, August, 9th. The company reported ($0.05) earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01. View Mast Therapeutics' Earnings History.
Where is Mast Therapeutics' stock going? Where will Mast Therapeutics' stock price be in 2017?
5 equities research analysts have issued 12-month price objectives for Mast Therapeutics' stock. Their predictions range from $0.09 to $5.00. On average, they anticipate Mast Therapeutics' share price to reach $2.52 in the next twelve months. View Analyst Ratings for Mast Therapeutics.
Who are some of Mast Therapeutics' key competitors?
Some companies that are related to Mast Therapeutics include Grifols, S.A. (GRFS), Jazz Pharmaceuticals PLC (JAZZ), SIGA Technologies (SIGA), Osiris Therapeutics (OSIR), VBI Vaccines (VBIV), Anavex Life Sciences Corp. (AVXL), Mirati Therapeutics (MRTX), XOMA Corporation (XOMA), ContraFect Corporation (CFRX), Aevi Genomic Medicine (GNMX), Ohr Pharmaceuticals (OHRP), Trillium Therapeutics (TRIL), Can Fite Biopharma Ltd (CANF), KaloBios Pharmaceuticals (KBIO), Mateon Therapeutics (MATN), Windtree Therapeutics (WINT), Affymax (AFFY) and Cubist Pharmaceuticals (CBST).
How do I buy Mast Therapeutics stock?
Shares of Mast Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mast Therapeutics' stock price today?
MarketBeat Community Rating for Mast Therapeutics (NYSE MSTX)MarketBeat's community ratings are surveys of what our community members think about Mast Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Mast Therapeutics stock can currently be purchased for approximately $0.13.
Consensus Ratings for Mast Therapeutics (NYSE:MSTX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||3 Hold Ratings, 2 Buy Ratings|
|Consensus Rating:||Hold (Score: 2.40)|
|Consensus Price Target: ||$2.52 (1,825.57% upside)|
Analysts' Ratings History for Mast Therapeutics (NYSE:MSTX)
(Data available from 7/25/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|1/19/2017||Canaccord Genuity||Reiterated Rating||Buy||N/A|
|10/14/2016||S&P Equity Research||Boost Price Target||$0.08 -> $0.09||N/A|
|9/23/2016||Cowen and Company||Downgrade||Outperform -> Market Perform||N/A|
|9/21/2016||Laidlaw||Downgrade||Buy -> Neutral||N/A|
|9/21/2016||Maxim Group||Downgrade||Buy -> Hold||N/A|
|8/1/2016||Roth Capital||Reiterated Rating||Buy||$2.00||N/A|
Earnings History for Mast Therapeutics (NYSE:MSTX)Earnings History by Quarter for Mast Therapeutics (NYSE MSTX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Mast Therapeutics (NYSE:MSTX)
Current Year EPS Consensus Estimate: $-0.160 EPS
Next Year EPS Consensus Estimate: $-0.170 EPS
Dividend History for Mast Therapeutics (NYSE:MSTX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Mast Therapeutics (NYSE:MSTX)Insider Trades by Quarter for Mast Therapeutics (NYSE:MSTX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/27/2015||Brandi Roberts||CFO||Buy||38,000||$0.50||$19,000.00|| |
Headline Trends for Mast Therapeutics (NYSE:MSTX)
Latest Headlines for Mast Therapeutics (NYSE:MSTX)
|Savara Announces Closing Of Merger With Mast Therapeutics - PR Newswire (press release)|
www.prnewswire.com - April 27 at 7:13 PM
|Savara Announces Closing Of Merger With Mast Therapeutics|
finance.yahoo.com - April 27 at 7:13 PM
|Mast Therapeutics And Savara Announce Anticipated Merger Exchange Ratio|
finance.yahoo.com - April 25 at 9:56 AM
|Mast Therapeutics Announces Adjournment Of Special Stockholders Meeting|
finance.yahoo.com - April 21 at 6:30 PM
|Mast Therapeutics (MSTX) Says it May Adjourn Special Meeting to Solicit Additional Votes For Merger With Savara - StreetInsider.com|
www.streetinsider.com - April 20 at 6:45 PM
|Mast Therapeutics Announces Possible Adjournment Of Special Stockholders Meeting To Solicit Additional Votes For Merger With Savara|
finance.yahoo.com - April 20 at 9:53 AM
|Mast Reminds Stockholders To Vote For The Proposed Merger With Savara|
finance.yahoo.com - April 17 at 10:07 AM
|Mast Therapeutics Inc (MSTX) Short Interest Update|
www.americanbankingnews.com - April 11 at 7:36 PM
|Leading Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Mast Therapeutics Stockholders …|
finance.yahoo.com - April 11 at 11:08 AM
|Leading Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Mast Therapeutics Stockholders Vote "FOR" The Proposed Merger And Related Proposals|
finance.yahoo.com - April 11 at 11:08 AM
|Mast Therapeutics And Savara Announce Approval To List Common Stock On The Nasdaq Capital Market|
finance.yahoo.com - April 10 at 10:19 AM
|MAST THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhi|
biz.yahoo.com - March 28 at 6:26 PM
|Mast Therapeutics Inc (MSTX) Given Average Rating of "Hold" by Brokerages|
www.americanbankingnews.com - March 27 at 2:35 PM
|Short Interest in Mast Therapeutics Inc (MSTX) Decreases By 0.8%|
www.americanbankingnews.com - March 25 at 7:14 AM
|Mast Therapeutics Sets Date For Special Meeting Of Stockholders To Vote On Proposed Merger With Savara|
us.rd.yahoo.com - March 16 at 9:08 AM
|Biotech and Pharmaceutical Stocks Fall on Pricing Concerns: Today's Research Reports on Celldex Therapeutics and Mast Therapeutics|
finance.yahoo.com - March 8 at 9:48 AM
|Mast Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results|
us.rd.yahoo.com - March 6 at 6:11 PM
|Mast Therapeutics Announces Clinical Study Of AIR001 For The Treatment Of Chronic Infection In Cystic Fibrosis Patients|
finance.yahoo.com - March 6 at 8:23 AM
|MAST THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits|
biz.yahoo.com - March 6 at 8:23 AM
|MAST THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits|
biz.yahoo.com - February 22 at 8:34 AM
|MAST THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Princi|
biz.yahoo.com - January 23 at 6:59 PM
Mast Therapeutics (MSTX) Chart for Tuesday, July, 25, 2017